CDC ENTEBBE

Payers increasingly use site-of-care (SOC) optimization to reduce healthcare costs by shifting patients from hospitals to ambulatory centers, where specialty pharmacies offer cost-effective, high-quality care. Ambulatory infusion centers (AICs) save payers and patients money, reduce hospital-acquired infections, and provide a supportive community for patients, enhancing both financial and human value in healthcare delivery.

Pfizer's Hympavzi, a once-weekly injection, received US approval for treating hemophilia A or B in patients aged 12 and older without inhibitors, costing $795,600 annually. It aims to reduce bleeding episodes and may offer convenience for hemophilia B patients. Despite modest commercial potential, it could carve out a niche in hemophilia B treatment.

13 studies in 14 publications reviewed, focusing on public and health care provider attitudes towards EUA products. 7 studies addressed public attitudes, understanding, and behaviors (RQ 1), finding concerns about safety and reduced willingness to use EUA products. 6 studies addressed health care provider attitudes, understanding, and behaviors (RQ 2), revealing some hesitancy due to EUA status but increased acceptance with more data. No studies addressed promotion of EUA products (RQ 3).

GLP-1 drugs like Wegovy and Ozempic may offer neuroprotective benefits beyond weight loss, potentially strengthening the blood-brain barrier and reducing inflammation, which could help prevent neurodegenerative diseases like Alzheimer's.

AstraZeneca to pay $2B to CSPC for a cardiovascular drug, Astellas Pharma licenses gene therapy from AviadoBio, Merck partners with Mestag Therapeutics for fibrosis treatments, Insitro signs three agreements with Eli Lilly for metabolic diseases, MiNK Therapeutics and Autonomous Therapeutics collaborate on metastatic tumors, Bayer and MOMA Therapeutics partner in oncology, Wonderskin names 5W Public Relations as AOR, Eversana signs with Oracle Argus Cloud, Qinotto and Eli Lilly collaborate, Onspire Health acquires Aesthetic Brand Marketing, Reunion Neuroscience partners with Seleni Institute, Danco Laboratories to seek FDA approval for Mifeprex use in miscarriages, Exact Sciences' Cologuard Plus wins FDA approval, Boehringer Ingelheim's survodutide gets Breakthrough Therapy designation, Lunds & Byerlys recalls Lone Star Dip, Kezar Life Sciences' zetomipzomib development halted by FDA, Bayer's elinzanetant NDA accepted by FDA, Biogen's felzartamab gets Breakthrough Therapy Designation, Black Diamond Therapeutics to cut jobs, Upstream Bio targets $182M for IPO, City Therapeutics launches with $135M, Purespring Therapeutics raises $105M, Judo Bio launches with $100M, Orasis Pharmaceuticals raises $78M, CAMP4 Therapeutics targets $67M for IPO, Basecamp Research closes $60M Series B, Arda Therapeutics raises $43M Series A, Crinetics Pharmaceuticals announces public offering, GSK to pay $2.2B to settle Zantac lawsuits, Scholar Rock's SMA drug shows muscle function improvement, CDC to screen travelers due to Marburg virus outbreak in Rwanda, Ad Council, AMA, and CDC launch flu vaccination campaign, Sage Therapeutics' Sage-718 fails in Alzheimer's study, WeightWatchers adds GLP-1 obesity treatments, Gritstone Bio files for Chapter 11, BioPharmCatalyst launches AI-powered chatbot Aiden, Otsuka Precision Health and Amalgam Rx launch Alzheimer's app Elevmi, PatientPoint unveils interactive communication solution, Curia rebrands, Switzerland's COMCO terminates Novartis investigation, Bluebird Bio's Skysona linked to blood cancer in seven children, Solera Health rebrands, HearingLife launches pickleball sweepstakes, Alfasigma launches Morpho brand, Healthy Minds Innovations launches Our World Of Emotions campaign.

Johnson & Johnson MedTech launches VOLT™ Variable Angle Optimized Locking Technology Plating System, designed to improve stability and efficiency in fracture care. The system offers enhanced construct stability, a range of plate shapes, and color-coded instruments for improved surgical workflow. Available initially for mini and small fragment fractures, with additional anatomic solutions planned for 2025.

GSK’s Arexvy showed sustained protection over three RSV seasons in adults 60+; 62.9% efficacy against RSV-related lower respiratory tract disease and 67.4% against severe RSV-LRTD after one dose. Mild-to-moderate adverse events were common, and revaccination may be needed.

Adione Juliet introduces a groundbreaking drug repurposing framework, reducing healthcare costs and improving access to essential medicines for marginalized communities. Her approach leverages advanced data analytics and AI, promising transformative impact on global health threats and healthcare disparities.

Pfizer pulled voxelotor, a sickle cell disease treatment, due to safety concerns, leaving patients and providers scrambling for alternatives. The community is rallying to maintain focus on finding a cure and increasing awareness of the disease.

CDC’s Advisory Committee on Immunization Practices may lower pneumococcal vaccination age from 65 to 50, enhancing public health and trust. The decision should empower doctors, not dictate from CDC headquarters.